Cerebrospinal fluid concentrations of soluble amyloid β-protein and apolipoprotein E in patients with Alzheimer's disease: Correlations with amyloid load in the brain

Archives of Neurology

Volumn 53, Issue 2, 1996, Pages 189-193

  Pirttila T ^a   Mehta, P D ^a   Soininen, H ^b   Kim, K S ^a   Heinonen, O ^b   Paljarvi L ^b   Kosunen, O ^b   Riekkinen Sr , P ^b   Wisniewski, H M ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CONGO RED;

ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD VESSEL; CEREBROSPINAL FLUID; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0030059065     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550020105022     Document Type: Article

References (33)

1. Segal MB. Extracellular and cerebrospinal fluids. J Inherit Metab Dis 1993; 16.617-638.
2. Watson MA, Scott MG Clinical utility of biochemical analysis of cerebrospinal fluid Clin Chem. 1995;41:343-360
3. Wisniewski HM, Wegiel J. The neuropathology of Alzheimer's disease. Neuroimaging Clin North Am 1995;5 45-57.
4. Selkoe D. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994;17:489-517.
5. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid β peptide isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90: 8098-8102.
6. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991,541.163-166.
7. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.
8. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotem E allele 4 with late-onset familial and sporadic Alzheimer's disease Neurology. 1993;43:1467-1472.
9. Van Nostrand WE, Wagner SL, Shankle WR, et al. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A. 1992;89:2551-2555.
10. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids Nature. 1992,359.325-327.
11. Mehta PD, Kim KS, Wisniewski HM ELISA as a laboratory test to aid the diagnosis of Alzheimer's disease. Techniques Diagn Pathol. 1991;2:99-112.
12. Pirttilä T, Mehta PD, Lehtimaki T, et al. Relationship between apolipoprotein E4 allele and CSF amyloid β-protein in Alzheimer's disease and controls. Neurosci Res Commun. 1994,15:201-207.
13. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype Ann Neurol 1995;37:512-518.
14. van Gool WA, Kuiper MA, Walstra GJM, Wolters E, Bolhuis PA. Concentrations of amyloid β protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;37:277-279
15. Nakamura T, Shoji M, Hangaya Y, et al. Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 1994; 36:903-911.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
17. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), II. standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
18. Soininen H, Reinikainen KJ, Partanen J, et al Slowing of electroencephalogram and choline acetyltransferase activity in post mortem frontal cortex in definite Alzheimer's disease. Neuroscience. 1992;49:529-535.
19. Mehta PD, Miller JA, Tourtellotte WW. Oligoclonal IgG bands in plaques from multiple sclerosis brains. Neurology. 1982;32:372-376
20. Pirttila T, Kim KS, Mehta PD, Frey H, Wisniewski HM. Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci. 1994;127:90-95.
21. Kim KS, Wen GY, Bancher C, et al. Detection and quantitation of amyloid β-peptide with two monoclonal antibodies. Neurosci Res Commun 1990;7 113-122.
22. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel D. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta. 1991;196:167-176.
23. Mahley RW, Innerarity TL, Rail SC Jr, Weisgraber KH. Plasma lipoprotein: apolipoprotein structure and function J Lipid Res. 1984;25:1277-1294
24. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
25. Hyman BT, Marzloff K, Arriagada PV The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution J Neuropathol Exp Neurol. 1993;52: 594-600.
26. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y High tissue content of soluble β1-40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994,145.452-460.
27. Tamaoka A, Kondo T, Odaka A, et al Biochemical evidence for the long-tail form (Aβ1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994;205:834-842.
28. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994;200:1598-1603.
29. Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid β. Biochem Biophys Res Commun 1993;197:1034-1040.
30. Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution J Neuropathol Exp Neurol. 1993;52. 594-600.
31. Wisniewski HM, Wegiel J. β-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol 1994,87:233-241.
32. Frackowiak J, Zoltowska A, Wisniewski HM. Non-tibullar β-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. J Neuropathol Exp Neurol. 1994;53:637-645.
33. Iwatsubo T, Mann DMA, Odaka A, Suzuki N, Ihara Y Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome Ann Neurol 1995; 37 294-299